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Abstract
Purpose This study aims to determine the optimal cryopres-
ervation protocol for whole ovaries intended for preservation
of fertility in women.
Methods We investigated the optimal cryopreservation proce-
dure for whole ovaries in a bovine model. The following pa-
rameters were investigated to determine their effect on ovarian
tissue viability: type of cryoprotectant, administration route of
the cryoprotectant (perfusion and/or submersion), and the
maximum tolerable interval between death of the animal and
start of the cryopreservation process. The resulting optimal
cryopreservation procedure for bovine ovaries was subse-
quently tested on human ovaries. In vitro glucose uptake, his-
tology, and immunohistochemistry were used to assess the
integrity of the ovarian tissue.
Results Starting the cryopreservation procedure (including
perfusion with and submersion in DMSO) within 10–15 min
after death of the animal proved critical, resulting in a 90–
100% protection level against cryodamage. When cryopre-
serving human ovaries using the same protocol, over 95%
protection against cryodamage was observed on all tissue
levels. In addition, no apparent morphological damage to ei-
ther the follicles or the vascular endothelium was observed.
Conclusion Our findings suggest that using the optimized proto-
col presented in this paper allows good cryopreservation of whole
human ovaries and represents an important step in considering
whole ovary autotransplantation for clinically applied fertility
preservation.
Keywords Whole ovary . Cryopreservation . Ischemia .
Bovine . Human
Introduction
With treatment modalities improving over the years, the num-
ber of cancer patients that survive their disease is increasing.
Parallel to this encouraging development, growing attention is
being given to the quality of life after cure, including the
ability to start a family. As some anti-cancer therapies may
reduce fertility or even lead to sterility, fertility preservation
should be offered prior to the start of these types of therapy. A
number of options for fertility preservations are currently
available to female patients [1–5]. Depending on age, the type
and stage of the cancer, and the stage of life, the most suitable
option will have to be selected for each patient individually.
Cryopreservation of cortical ovarian tissue strips is one op-
tion for fertility preservation. These tissue strips can, after the
patient has been cured of her disease, be thawed and
autotransplanted to restore fertility. To date, this option for fer-
tility preservation has already led to the birth of at least 86
children worldwide, indicating the viability of this option [6–8].
The major problem occurring when retransplanting ovarian
cortical tissue is the occurrence of ischemia [9]. After surgery, it
takes about a week for the strip(s) to become sufficiently
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vascularized.Duringthisperiod,manyfollicles in thegraftarelost
due to ischemia, thereby limiting the time the graft functions
physiologically. The life span of a graft ranges between several
months up to 7 years [10–15], after which subsequent
autotransplantations may be required to restore fertility.
An alternative for the cryopreservation of ovarian cortical
strips is the cryopreservation and subsequent autotransplantation
of a whole ovary including the vascular pedicle [16–20]. As the
vascular pedicle of the ovary is surgically attached to the circula-
tion, thiswill result in an immediate restorationof theoxygenand
nutrient supply to the graft. Consequently, ischemic damagewill
be kept to aminimum.
The successful cryopreservation and subsequent thawing of
an organ the size of an whole human ovary, however, is no
small feat. Proof of concept of the procedure has been provid-
ed by Imhof et al. [17] and others [19–22], who were able to
cryopreserve and retransplant an intact ovine ovary. However,
as an ovine ovary is considerably smaller than a human ovary
[23], the cryopreservation of a human ovary has proven to be
technically much more complicated. The delivery of sufficient
amounts of cryoprotectant to the entire ovary will prove to be
challenging. In addition, the requirements for protection
against cryodamage may actually differ for the different cellu-
lar components of the ovary, i.e., the follicles/oocytes, the
stromal cell compartment, and the vascular bed. Bedaiwy
et al. [21] and Martinez-Madrid et al. [24, 25] have both made
a first attempt at cryopreserving intact human ovaries by per-
fusing them with a 10% DMSO solution. In these studies,
cryodamage of the ovarian tissue was assessed by viability
tests, electron microscopy, and analysis of cells undergoing
apoptosis, indicating minor damage to the tissue.
For the development of an optimal cryopreservation proce-
dure, it is not possible to use large numbers of human ovaries
for both ethical and practical reasons. We therefore initially
resorted to a bovine animal model, as these ovaries are very
similar to human ovaries in several aspects [23]. Our results
may expedite the application of whole ovary cryopreservation
and autotransplantation to clinical use.
Materials and methods
Experimental design
We collected bovine and human intact ovaries and subjected
these ovaries to different cryopreservation protocols. The level
of protection against cryodamage that was achieved by applying
these different protocols was assessed by three different assays.
We used a glucose uptake assay to determine the viability of
stromal ovarian tissue (human and bovine tissue), and histolog-
ical analysis was performed to assess the condition of follicles
(human and bovine tissue) and immunohistochemistry (human
tissue only) to determine the integrity of the ovarian vasculature.
Using these techniques, we tested the effect on the degree
of protection against cryodamage in frozen and thawed intact
bovine ovaries in four separate and subsequent sets of exper-
iments (A–D):
A. Submersion in different types of cryoprotectant prior to
cryopreservation (outlined in Table 1); intact bovine ova-
ries were submerged in a 10% solution of four different
cryoprotectants for at least 15 min
B. Perfusion of bovine ovaries with cryoprotectant (Table 2);
using the best cryoprotectants identified in experiment 1,
we tested the additional effect of perfusion with cryopro-
tectant in combination with submersion in cryoprotectant
C. The duration of the combined submersion and perfusion
treatment with bovine ovaries
D. The duration of the ischemic period between death of the
animal and start of the cryopreservation process (both in
Table 3)
Collection of bovine ovaries
Intact bovine ovaries were collected at a local abattoir essentially
as describedpreviously [23, 26].Briefly,whole ovarieswith their
vascular pedicle used for culturing fresh ovarian cortical, subcor-
tical, and medullar biopsies were collected on ice. Ovaries used
for cryopreservation experiments were perfused on site with
15 ml of Ringer’s solution (Baxter, Utrecht, The Netherlands)
containing 50 IE/ml heparin (Leo Pharma, Breda,
The Netherlands) and 2.5%methylene blue (Clinical Pharmacy,
Nijmegen, The Netherlands) via the vena ovarica, until a blue
discoloration of the tissue was observed (usually within 2–
3 min). The time between death of the animal and start of the
perfusion was kept to a minimum but was dependent on the
workflow in the abattoir (40–50 min). In a separate set of exper-
iments, we were able to obtain the bovine ovaries within 10–
15minafter thedeathof theanimal, thusenablingamuchquicker
start of the onsite perfusion with heparin. The efficiency of the
perfusion was monitored by the appearance of blue coloration at
the surface of the ovary. After the perfusion, the ovaries were
transported on ice to the laboratory for further processing.
Human ovaries
Six human ovaries were obtained from three different patients
opting for preventive gonadectomy (two BRCA1 patients and
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one patient with breast cancer; aged 45, 41, and 35 years,
respectively) from the Streekziekenhuis Koningin Beatrix,
Winterswijk (The Netherlands). Informed consent was obtain-
ed from each patient. Approval for the procedure was obtained
from the local medical ethical committee, provided that the
procedure would not interfere with the required diagnostic
histology.
One ovary of each patient was used to prepare fresh tissue
fragments. From the other ovary (which was to be cryopre-
served), the vascular pedicle was dissected, and an 18 GA
1.77, 1.3 × 35 mm cannula (Venflon, Becton Dickinson,
Breda, The Netherlands) was inserted in the arteria ovarica.
The ovary was perfused for 5 min with a heparin/methylene
blue solution as described for the bovine ovaries. The perfu-
sion was performed within 5 min after the extirpation of the
ovary. After perfusion, both ovaries were stored on ice and
transported to the laboratory.
Cryopreservation and thawing of intact bovine
and human ovaries
For submersion experiments, the bovine ovaries were placed
in a bath containing 30 ml of Dulbecco’s modified Eagle’s
medium (DMEM; PAA Laboratories, Pasching, Austria)/2%
fetal calf serum (FCS; Gibco, Breda, The Netherlands) with-
out any cryoprotective agent (n = 5), or in the presence of 10%
cryoprotective agent, including dimethyl sulfoxide (DMSO;
Sigma-Aldrich, Zwijndrecht, The Netherlands) (n = 5),
propanediol (n = 4), ethylene glycol (n = 4), or butanediol
(n = 4). Submersion time was varied between 15 and
180min. Subsequently, the ovaries were transferred to a sterile
100-ml container (Deltalab, Barcelona, Spain) containing
DMEM/2% FCS with or without 10% of the cryoprotectants
mentioned above. The container was then placed into a pas-
sive cooling device (5100 Cryo Freezing Container; Nalgene,
VWR, Belgium) precooled to 0 °C. Subsequently, the contain-
er was transferred to a −80 °C freezer overnight to allow for a
gradual decrease in temperature (detailed in Gerritse et al.
[26]). The container with the ovary was then submerged in
liquid nitrogen and stored for at least 1 week.
Perfusion of the bovine ovaries was performed by inserting
a blunt-ended needle (23 g olive tipped cannula curved, Aspen
Medical, USA) into the arteria ovarica and secured using a
small clamp [23]. All vessels other than the vena ovarica and
the arteria ovarica were occluded using clamps. Perfusion time
was varied between 15 and 120 min with a solution of DMEM
supplemented with 2% FCS, 2.5% methylene blue, and 10%
DMSO or ethylene glycol, using a peristaltic STC-521 syringe
pump (Terufusion, Tokyo, Japan), at a flow rate of 2.5 ml/min.
During perfusion, the bovine ovaries were submerged in the
same solution as the perfusion fluid, only without the methy-
lene blue. During perfusion, we observed backflow of the
(blue) perfusion fluid from the vein. No leakage of perfusion
fluid from the clamped vessels was observed, illustrating the
efficiency of the procedure. After the perfusion, the ovaries
Table 2 Experimental design (Fig. 2)
Condition Number of ovaries Submersion Perfusion Cryoprotectant Concentration (%) Time of submersion and/or perfusion (min)
1 (+ control) 6 na na na na na
2 (− control) 5 − − − − 0
3 5 + − DMSO 10 15
4 5 + + DMSO 10 30
5 3 + + Ethylene glycol 10 30
na not applicable
Table 1 Experimental design (Fig. 1)
Condition Number of ovaries Submersion Perfusion Cryoprotectant Concentration (%) Time of submersion and/or perfusion (min)
1 (+ control) 6 na na na na na
2 (− control) 5 − − − − 0
3 5 + − DMSO 10 15
4 4 + − Propanediol 10 15
5 4 + − Ethylene glycol 10 15
6 4 + − Butanediol 10 15
na not applicable
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(with the blunt-ended needle still inserted) were transferred to
a sterile 100-ml container (Deltalab, Barcelona, Spain) con-
taining DMEM/2% FCS with or without 10% of the cryopro-
tectants mentioned above and were frozen as described previ-
ously for the submersion experiments.
Extrapolating on our experimental results regarding glu-
cose uptake by bovine ovaries, human ovaries were perfused
with, and submerged in, a 10% DMSO solution for 60 min.
Thawing of whole bovine and human ovaries was per-
formed basically as described by Martinez-Madrid et al.
[25]. The ovaries were placed in a water bath at 60 °C for
approximately 10 min, until most of the ice surrounding the
ovary had melted, leaving the ovary still frozen. Next, ovaries
were incubated in a water bath at 37 °C for 20 min, until the
tissue was completely thawed. Subsequently, the ovary was
taken from the container, submerged in 30 ml of DMEM/2%
FCS, and reconnected to the peristaltic pump. The cryopro-
tectant was gradually removed by three subsequent perfusion
steps of 10 min each at room temperature with a flow rate of
2.5 ml/min using DMEM/2% FCS with 0.25 M of sucrose,
DMEM/2% FCS with 0.1 M of sucrose, and DMEM/2% FCS
without sucrose, respectively.
After perfusion, ovarian biopsies were prepared and cul-
tured as described below.
Preparation and culturing of ovarian biopsies to assess
glucose uptake
Uptake of glucose by cultured ovarian tissue fragments was
performed essentially as described [26]. Briefly, from either
fresh or cryopreserved/thawed ovaries, end-to-end tissue rods
were prepared with a 6-mm-diameter biopsy punch (Kai
Medical, Solingen, Germany) and divided in two cortex frag-
ments, two subcortex fragments, and two medulla fragments,
each 2–3 mm long. Biopsies were transferred to six-well
plates (Falcon, Heidelberg, Germany) for culturing.
Duplicate wells were prepared for each ovary. Each well
contained either three cortical, three subcortical, or three
medullar biopsies from the same ovary, in 5 ml of DMEM
culture medium supplemented with 10% FCS and 40 μg/ml
gentamicin. At day 4, the culture was ended and the glucose
content of culture supernatants was determined using a stan-
dard blood gas analyzer (Chiron Diagnostics, Bayer,
Germany). At the end of the culture period, biopsies were
weighed, and glucose uptake was normalized (and expressed)
per milligram tissue per hour. Protection levels were expressed
as a percentage of glucose uptake by fresh tissue.
(Immuno)-histochemical staining of ovarian tissue
To highlight blood vessel endothelial cells and follicles, tissue
sections of both fresh and cryopreserved/thawed fragments of
human ovaries were fixed overnight in phosphate-buffered
4% formaldehyde and embedded in paraffin. Five-
micrometer sections were stained with anti-human factor
VIII to visualize the vascular endothelium [23].
For the analysis of follicle integrity, 7-μm sections of either
bovine or human ovarian cortex were stained with hematox-
ylin and eosin. To prevent counting a follicle twice, each sub-
sequent section was separated by 100 μm of tissue. The per-
centage of morphologically normal and degenerated (i.e.,
showing cytoplasm shrinkage, disorganized granulosa cells,
or pyknotic nuclei) primordial, primary, secondary, and antral
follicles was determined according to predefined criteria [27],
by two independent observers. The mean value is presented.
The percentage rather than the total number of follicles was
determined as the distribution of follicles in cortex fragments
of the same ovary may vary more than 2 orders of magnitude
[28, 29]. All sections were examined by conventional light
microscopy (×100).
Table 3 Experimental design (Fig. 3)
Condition LI or SI Number of ovaries Submersion Perfusion Cryoprotectant Concentration (%) Time of submersion and/or perfusion (min)
1 (+ control) LI 10 na na na na na
SI 7
2 (− control) LI 5 − − − − −
SI 5
3 LI 5 + + DMSO 10 30
SI 6
4 LI nd na na na na na
SI 6 + + DMSO 10 60
5 LI 5 + + DMSO 10 120
SI 7
In all experiments, fresh (i.e., not cryopreserved) tissue was used as a positive control, and tissue with experimentally induced maximal cryodamage was
used as a negative control
na not applicable, nd not done, LI long period of ischemia, SI short period of ischemia
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Statistical analysis
Data were tested for normality using GraphPad Prism (version
5.13) for Windows (GraphPad Software, San Diego, CA,
USA) and found to be normal. Two-sided Student’s t test
was performed using the same software package. P < 0.05
was considered to be statistically significant.
Results
Protection against cryodamage by different cryoprotective
agents
In previous work, we have shown that submerging an intact
bovine ovary in a 10% DMSO solution for 15 min fully
protected the cortical layer of the ovary, while leaving deeper
(subcortical and medullar) tissue layers unprotected against
cryodamage [26]. We tried to extend the level of protection
by testing three other cryoprotective agents that were previ-
ously used in analogous studies [30, 31] and comparing them
with DMSO. As shown in Fig. 1, freezing a bovine ovary
without any protective measures diminished its glucose up-
take in the 4 days of culture by more than 80% on all tissue
levels (condition 1 versus 2). In line with our previous work,
submerging the ovary for 15min in DMSO (condition 3) prior
to cryopreservation completely protected the ovarian cortex
but did not protect the subcortical and the medullar tissue
layers. Substituting DMSO with either propanediol (condition
4) or butanediol (condition 6) did not provide protection on
either tissue level. Using ethylene glycol (condition 5) resulted
in a varying protection level for the cortical tissue. In four
different ovaries, a protection level of between 19 and 93%
(mean 59%) was found, which was statistically different from
fresh tissue (P < 0.001). On the subcortical and medullar
layers, no protective effect was observed (Fig. 1, middle and
right panels; P < 0.001). Unexpectedly, the levels of glucose
uptake of subcortical and medullar tissues derived from ova-
ries treated with ethylene glycol, propanediol, or butanediol
were lower than the glucose uptake in tissue frozen and
thawed without any protection against cryodamage.
However, these differences did not reach statistical signifi-
cance (P > 0.05).
Whereas a submersion time of 15 min is sufficient for
DMSO to obtain maximum protection in the cortical layer
(Fig. 1, left panel), the other cryoprotective agents might re-
quire a longer incubation time to achieve protection. To test
this, we repeated the experiment with a submersion period of
3 h. The results were basically identical to the previous exper-
iment, i.e., full protection of cortical tissue by DMSO, some
Fig. 1 In vitro glucose uptake of ovarian tissue fragments derived from
bovine ovaries submerged in cryoprotectants. Fresh ovaries (condition 1;
positive control, white bars); ovaries cryopreserved and thawed without
any protection (condition 2; negative control, black bars); from ovaries
submerged in a solution containing 10% DMSO (condition 3),
propanediol (condition 4), ethylene glycol (condition 5), or butanediol
(condition 6) for 15 min prior to cryopreservation. Tissue fragments
were collected from the ovarian cortex (left panel), the subcortex
(middle panel), and the medulla (right panel). Shown is the mean ±SD;
the number above bars represents the number of tested ovaries per
condition. Statistically significant differences from glucose uptake by
fresh tissue are shown in bars; *P < 0.05; **P < 0.001; NS no
statistical significance. Note the complete protection against
cryodamage of cortical fragments derived from ovaries submerged in
DMSO (condition 3) and the limited protection by submersion in
ethylene glycol (condition 5). The other cryoprotectants displayed no
protection at all (conditions 4 and 6). In the deeper tissue layers (middle
and right panels), protection against cryodamage by submersion was not
observed with any of the cryoprotectants used
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protection of the cortex by ethylene glycol, and no protective
effect with the other cryoprotective agents (data not shown).
Combining submersion with perfusion of whole ovaries
increases the protective effect of DMSO and ethylene
glycol in the subcortical and medullar tissues
In a previous report [26], we have shown that a combination of
submerging and perfusion with a solution containing 10%
DMSO extended the protective effect to the deeper tissue
layers of an intact bovine ovary. In the next set of experiments,
we therefore analyzed the protective effect of combining sub-
mersion and perfusion with ethylene glycol, using the same
treatment with DMSO as a reference (Fig. 2). Submersion in
10% DMSO for only 15 min (condition 3) fully protected the
cortical ovarian layer (left panel) while not protecting the
subcortex (middle panel) or medulla (right panel).
Combining submersion and perfusion in/with DMSO for
30 min (condition 4) still resulted in full protection of the
cortex, while only partially protecting the subcortex and me-
dulla for 66 and 60%, respectively. Combining submersion
and perfusion with ethylene glycol (condition 5) increased
the protection of deeper layers compared with submersion
only from 5 to 36% for the subcortex and from 7 to 33% for
the medulla. The level of cryoprotection for the subcortex and
the medulla with submersion/perfusion with ethylene glycol
(condition 5) was considerably less than the protection level
achieved by DMSO submersion/perfusion (condition 4). Note
that due to the lack of cryoprotection by butanediol or
propanediol in the submersion experiments (Fig. 1), these
compounds were not further used in the subsequent perfusion
experiments shown in Fig. 2.
Time between removal of the ovary and start
of the heparin perfusion is crucial for successful
cryopreservation of the entire ovary
From the experiments described above, we concluded that
DMSO was superior to the other tested cryoprotective agents
and, therefore, the cryoprotectant of choice for further optimi-
zation of the cryopreservation process. Even with DMSO,
however, we did not succeed in increasing protection levels
of the subcortex and the medulla beyond the 66%mark, which
was statistically different from fresh tissue (P < 0.05; Fig. 2,
condition 4 in the middle and right panels). We therefore also
investigated the possible negative effect of the relatively long
time period of warm ischemia at the abattoir (30–50 min)
between the death of the animal and the moment when we
could obtain its ovaries for further processing. Eventually,
however, we were able to obtain the ovaries 10–15 min after
Fig. 2 In vitro glucose uptake of ovarian tissue fragments derived from
bovine ovaries submerged in, and perfused with, cryoprotectants. Fresh
ovaries (condition 1; positive control, white bars); ovaries cryopreserved
and thawed without any protection (condition 2; negative control, black
bars); from ovaries submerged in a solution containing 10% DMSO for
15 min prior to cryopreservation (condition 3, gray bars). Ovaries
submerged in, and perfused with, 10% DMSO for 30 min are shown as
condition 4 (checkered bars) and ovaries submerged in, and perfused
with, 10% ethylene glycol for 30 min are shown as condition 5 (striped
bars). Tissue fragments were collected from the ovarian cortex (left
panel), the subcortex (middle panel), and the medulla (right panel).
Shown is the mean ±SD; the number above bars represents the number
of tested ovaries per condition. Statistically significant differences from
glucose uptake by fresh tissue are shown in bars; *P < 0.05; **P < 0.001;
NS no statistical significance. Note the complete protection against
cryodamage of cortical fragments derived from ovaries after submersion
in and perfusion with DMSO and the partial protection of the subcortex
and the medulla (condition 4). With ethylene glycol only, approximately
50% of the protection level obtained with DMSO was observed
(condition 5)
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death of the animal, thereby minimizing the period of warm
ischemia. With these so-called Bshort ischemic (SI) ovaries,^
we repeated a number of experiments that were previously
performed with Blong ischemic (LI) ovaries^ (i.e., ovaries
obtained 30–50 min after death), using DMSO as a cryopro-
tectant. Results are shown in Fig. 3.
The glucose uptake of fresh SI ovaries (i.e., obtained 10–
15 min after death; Fig. 3, condition 1, black bars) was signif-
icantly (P ≤ 0.0001) higher than the glucose uptake of fresh LI
ovaries (i.e., obtained 30–50min after death; condition 1, gray
bars). This was apparent in all three tissue layers. After
submerging/perfusing the LI ovaries for 30 or 120 min with
10% DMSO, we observed a completely protected cortex (up-
per panel, gray bars) and partially protected subcortex (middle
panel, gray bars) and medulla (lower panel, gray bars).
Although prolonging the incubation from 30 min (condition
3) to 120 min (condition 5) led to a slight increase of the
protection level (from 60 to about 75%), complete protection
was not achieved and a statistically significant difference with
the glucose uptake by fresh tissue remained (P < 0.05). After
repeating this experiment with SI (black bars) instead of LI
(gray bars) ovaries, we observed a partial protection after sub-
merging and perfusion with DMSO after 30 min (condition 3,
black bars), but after a 120-min (condition 5, black bars) in-
cubation time, a protection level of over 90% was achieved in
all three tissue layers that was statistically not different from
the glucose uptake by fresh tissue of SI ovaries (P > 0.05).
Considering the possible toxic side effects of DMSO, our aim
was to keep the incubation time with DMSO as short as pos-
sible. We therefore also tested the protective effect of
submersion/perfusion on SI ovaries for an intermediate period
of 60 min (condition 4, black bars). As shown in fig. 3, the
protection levels obtained with this procedure were compara-
ble to a 120-min incubation and statistically not different
(P > 0.05) from the levels of fresh tissue in all three layers
(condition 1).
In bovine ovaries cryopreserved via the most optimal pro-
cedure (i.e., the interval between death and start of cryopres-
ervation procedure less than 20 min, and 60 min perfusion/
submersion in 10% DMSO), we performed a histological
analysis of follicle condition (Fig. 4).
The optimized DMSO submerging and perfusion protocol
also fully protects human ovaries against cryodamage
After establishing the optimal procedure to protect intact bo-
vine ovaries against cryodamage during cryopreservation, we
cryopreserved intact ovaries from three women, using the op-
timal protocol we established in the bovine model system as
described above. From each patient, one ovary was used to
prepare tissue fragments that were cultured fresh (positive
control), whereas the contralateral ovary was perfused with
heparin and cryopreserved using a combination of 10%
DMSO for submersion and perfusion for 60 min.
Considering the importance of starting the perfusion with hep-
arin as soon as possible after obtaining the ovary, this perfu-
sion was performed in the operation room, only minutes after
the ovaries had been surgically removed. As judged by the
blue coloration of the ovary during the perfusion with heparin/
methylene blue, the perfusion of the ovary used for cryopres-
ervation of patient 1 was not completely successful, as only
part of the ovary turned blue. The ovaries that were to be
cryopreserved from patients 2 and 3, on the other hand, turned
completely blue shortly after start of the perfusion, indicating
Fig. 3 The effect of warm ischemia and length of the perfusion time with
cryoprotectant on whole ovary viability. In vitro glucose uptake of
ovarian tissue fragments from bovine ovaries derived from animals that
were processed (perfused with heparin and transferred to ice) 30–50 min
after death (gray bars; Blong ischemic (LI) ovaries^) versus 15–20 min
after death (black bars; Bshort ischemic (SI) ovaries^). Fresh ovaries
(condition 1; positive control); ovaries cryopreserved and thawed
without any protection (condition 2; negative control); from ovaries
submerged in, and perfused with, 10% DMSO for 30 min (condition 3)
or 60 min (condition 4) or 120 min (condition 5) prior to
cryopreservation. Shown is the mean ±SD; the number above bars
represents the number of tested ovaries per condition. Statistically
significant differences from glucose uptake by fresh tissue are shown in
bars; *P < 0.05; **P < 0.001; NS no statistical significance. Note the
increased glucose uptake of fresh SI ovarian tissue compared to fresh LI
ovarian tissue (condition 1). Also, the DMSO-mediated protection levels
against cryodamage are much higher (>95% protection) in the SI ovarian
tissue, compared to LI ovarian tissue (50–70% protection)
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that the perfusion procedure had been successful. In Fig. 5, the
glucose uptake of the tissue fragments of the fresh (non-
cryopreserved) ovaries was set at 100% to enable inter-
patient comparisons. In patient 1, the cortical layer of the
ovary was fully protected against cryodamage (upper panel,
left bar), whereas in the subcortex (middle panel, left bar) and
the medulla (bottom panel, left bar), protection levels of only
30–40% were achieved. In patients 2 and 3, on the other hand,
all three ovarian tissue layers were protected for 90–100% by
applying our optimized cryopreservation protocol.
The cryopreservation procedure causes no visible damage
to either follicles or the vascular endothelium
in the human ovarian tissue
We counted the number of follicles in 15 hematoxylin and
eosin-stained sections (100 μm apart) from the fresh, non-
cryopreserved ovaries of the three patients. It should be noted
that, as all three patients were of relatively advanced age, the
number of observed follicles was limited. We therefore decid-
ed to count all follicles in the 15 tissue sections, rather than a
fixed number for each patient (number of counted follicles is
shown in Table 4). Our results showed that more than 90% of
the follicles were morphologically normal, whereas less than
10% showed cytoplasm shrinkage, disorganized granulosa
cells, or pyknotic nuclei as a sign of follicle degeneration
(Fig. 6, Table 4). After cryopreservation and thawing of the
suboptimal perfused ovary of patient 1, the percentage of
morphologically normal primordial/primary follicles was
81%, whereas the optimally perfused ovaries of patient 2
and patient 3 contained 96 and 90% morphologically normal
primordial/primary follicles, respectively. Of the follicles ob-
served (n = 613), 95% was at the primordial or primary stage.
Damage to the vascular component of the ovary could be a
side effect of a prolonged incubation time with DMSO [32].
To assess damage to the endothelium, we performed immu-
nohistochemical staining with anti-human factor VIII anti-
body in fresh as well as cryopreserved and thawed human
ovarian tissue. As shown in Fig. 7, no detached endothelial
cells or other apparent damage to the endothelial cell lining
was visible.
Discussion
In this paper, we present a procedure to cryopreserve and thaw
an intact ovary without apparent cryodamage.We found it was
crucial to confine the period of warm ischemia to an absolute
minimum. Submersion in, and perfusion with, 10% DMSO
for 60 min was required for a complete protection against
cryodamage on all tissue levels.
A comparable perfusion time (40 min) required for optimal
cryopreservation of bovine ovaries with DMSO was reported
by Zhang et al. [33, 34]. While the majority of our data was
obtained using bovine ovaries as a model system, our final
experiments with human ovaries show that our bovine data
actually can be extrapolated to the human situation.
We have shown that whereas the vasculature of two human
ovaries was colored blue in their entirety by the methylene
blue/heparin perfusion fluid, the vasculature of the third ovary
was only partly colored. This observation was in accordance
with the less successful cryopreservation (based on its glucose
uptake) of the latter ovary. Most likely, clot formation had
occurred in this ovary, thereby not only preventing the
heparin/methylene blue solution to completely perfuse the
ovary but also hindering the subsequent perfusion with the
cryoprotectant solution. Preventing clotting is an important
factor in not only the cryopreservation procedure but also post
autotransplantation [20]. Clearly, a functional vascular bed of
the ovary is evidently a prerequisite for several crucial steps in
a b c
Fig. 4 Follicle morphology before and after cryopreservation/thawing of
bovine ovaries. Histological hematoxylin and eosin-stained 7-μM
sections were prepared from cortical tissue of fresh (a) and
cryopreserved/thawed bovine ovaries without any cryoprotectant (b)
and bovine ovaries cryopreserved under optimal conditions (c). The
vast majority of observed follicles were found to be in the primordial/
primary stage of development. In b, obvious signs of follicle degeneration
can be observed (pyknotic nuclei and granulose cells that are detached
from the follicle wall), which are lacking in a, c. Bars represent 50 μM
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the cryopreservation/thawing and autotransplantation
procedure.
Another factor in our model system which proved to be
essential for successful cryopreservation was the duration of
the warm ischemic period between death of the animal and
cooling of the tissue. By reducing this period of time as much
as technically possible, the glucose uptake of the fresh tissue
increased considerably. In addition, submersion in, and perfu-
sion with, DMSO resulted in full protection of the glucose
uptake of this less ischemic tissue after cryopreservation and
thawing. When surgically removing a human ovary for cryo-
preservation, there should be no time loss between removal of
the ovary from its vascular pedicle and start of the perfusion in
order to keep the warm ischemic period as short as possible.
The detached ovary should obviously not be left in the ab-
dominal cavity during prolonged surgery but should be trans-
ferred to cold (0 °C) medium without delay. In addition, the
level of experience of the person performing the perfusion
procedure is an important factor in the efficacy and efficiency
of intact ovary perfusion [35].
As far as the choice of the cryoprotectant is concerned, our
results indicate that butanediol and propanediol should not be
used. While we observed some cryoprotective effect of ethyl-
ene glycol, in our study, DMSO proved to be clearly superior.
In two large European centers for cryopreservation of human
ovarian cortex strips, both these cryoprotectants are being
used [36, 37]. Both centers have reported several pregnancies
after autotransplantation of ovarian tissue fragments [15, 38,
39], indicating that they are both successful in cryopreserving
human ovarian tissue. The relative lack of protection against
cryodamage which we observed with ethylene glycol may be
explained by the fact that we cryopreserved intact ovaries
rather than isolated ovarian cortex strips.
Our findings are predominantly based on our glucose up-
take assay as a readout system for cryodamage [26]. This
assay has been successfully used to quantify cryodamage in
ovarian tissue in several other studies [40–43]. As stromal
cells comprise more than 90% of the ovarian volume, it is safe
to say that this assay predominantly provides information on
the viability of the stromal cell compartment. Assays that
combine the assessment of glucose uptake with histology,
such as the methylthiazolyl blue tetrazolium (MTT) assay
described by Torre et al. [35, 44], may provide valuable addi-
tional information on the condition and viability of the ovarian
tissue.
Obviously, the condition of the follicles, the internal ovar-
ian vasculature, and the vascular pedicle will also have to be
assessed before cryopreservation and, consecutively,
autotransplantation of an intact human ovary can be per-
formed. Although immunohistochemical evaluation of the in-
tegrity of the vascular endothelial lining of both large and
small blood vessels did not show any gross irregularities in
human cryopreserved ovaries, morphological assessment
Fig. 5 In vitro glucose uptake by fresh and cryopreserved human ovarian
tissue. Ovaries were derived from three different patients that had both of
their ovaries prophylactically removed. One ovary from each patient was
used to prepare fresh tissue fragments (positive control), and the glucose
uptake of these fresh fragments was set at 100%. The contralateral ovary
of each patient was treated following the optimized cryopreservation
protocol by submersion in, and perfusion with, a 10% DMSO solution
during 60 min prior to cryopreservation. After cryopreservation/thawing,
tissue fragments (of the cortex, subcortex, and medulla) were prepared
and cultured. Glucose uptake is expressed as a percentage of the uptake
by fresh tissue. Note the complete protection against cryodamage in
patients 2 and 3 at all tissue levels, whereas the subcortical and
medullar tissue from the suboptimal perfused ovary of patient 1
appeared to have sustained considerable cryodamage, as reflected by
the diminished level of glucose uptake
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alone is most probably not sufficient. In previous reports, a
number of techniques have been used to demonstrate that not
only the cryopreservation process itself but also the perfusion
technique that is used to saturate the intact ovine ovaries with
cryoprotectant, inflicted damage on several levels [32, 45, 46].
Evidence of vascular damage in cryopreserved ovine ovaries
was demonstrated by Onions et al. [32], by the extravasation
of fluorescent microspheres, and the presence of clots in cryo-
preserved ovaries. However, a recent report on the successful
cryopreservation and autotransplantation of intact sheep ova-
ries leading to restoration of ovarian function and birth of
normal offspring used DMSO as a cryoprotectant [20] indi-
cates that despite its potential toxic side effects, DMSO can
actually be used to successfully cryopreserve intact ovaries of
a large mammal.
The possible toxicity of DMSO may be considered a con-
traindication for the use of this cryoprotectant in the cryopres-
ervation of human cells, tissue fragment, and in our case,
intact organs. Although toxicity of DMSO has indeed been
demonstrated in a number of instances, there are now also data
available indicating that DMSO toxicity may not be a major
factor in the cryopreservation of (human) reproductive tissue.
DMSO is widely used in the cryopreservation of human sur-
plus embryos derived from IVF procedures. In addition, the
majority of children that were born after autotransplantation of
ovarian cortical tissue were derived from tissue that was cryo-
preserved using DMSO as a cryoprotectant. Should, however,
major issues concerning the use DMSO arise in the future, the
use of less or even non-toxic alternatives such as trehalose
should be further investigated [47].
a b
c d
Fig. 6 Follicle morphology
before and after cryopreservation/
thawing of human ovaries.
Histological hematoxylin and
eosin-stained 7-μM sections were
prepared from cortical tissue of
fresh (a, c) and cryopreserved/
thawed human ovaries (b, d). In
a, b, primordial follicles with
pyknotic nuclei (black
arrowheads) and cytoplasmic
shrinkage/detached granulose
cells (white arrowhead) are
indicated. In c, d, more advanced
stages of follicular development
are shown next to primordial
follicles. Bars represent 100 μM
Table 4 Percentage of morphologically normal follicles in cortical fragments of control ovaries and the contralateral cryopreserved/thawed ovaries of three
patients. The number of degenerated follicles and the total number of counted follicles are indicated. Follicles were classified according to Gougeon [27]
Primordial Primary Secondary Antral
Patient 1
Control ovary 89% (4/34) 94% (1/16) 100% (0/1) 0/0
Cryopreserved ovary 77% (15/50) 97% (1/34) 95% (1/19) 100% (0/3)
Patient 2
Control ovary 98% (2/105) 100% (0/19) 100% (0/3) 0/0
Cryopreserved ovary 96% (5/137) 100% (0/2) 0/0 0/0
Patient 3
Control ovary 100% (0/64) 100% (0/8) 100% (0/2) 0/0
Cryopreserved ovary 90% (11/109) 100% (0/6) 100% (0/1) 0/0
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The transplantation of a non-cryopreserved, fresh intact
human ovary is, in fact, technically possible as shown by
Silber and Gosden [48] and Silber et al. [49], who per-
formed this procedure on identical twin sisters, resulting
in healthy offspring. When autotransplanting frozen/
thawed intact ovaries derived from cancer patients, how-
ever, there are two additional important issues that should
be addressed.
First, tumor cells, possibly leading to reintroduction of the
malignancy after autotransplantation, may be present in the
ovarian tissue. The number of metastasized tumor cells is very
likely related to the tissue volume that is autotransplanted.
Consequently, autotransplanting a whole ovary poses a much
higher risk compared to the much smaller ovarian cortical
strips. Whole ovarian autotransplantation should therefore on-
ly be offered to cancer patients when ovarian involvement can
be virtually excluded. In a systematic review on the chance of
different tumor types metastasizing in the ovary we performed
[50], we show that information regarding the metastasizing
capacity of most types of primary tumors is either incomplete
or lacking completely. We therefore recommend that until our
knowledge on this subject has been improved, whole ovary
autotransplantation can only be carried out safely on benign
indication.
Secondly, the inherent risk with cryopreserving and
autotransplanting a whole ovary is that any calamity that
may occur during the procedure results in the loss of all the
oocytes that are present in the ovary. Clot formation during the
autotransplantation is, in this respect, the most prominent risk.
In clinical practice, therefore, we suggest that for the time
being, whole ovary autotransplantation should be offered only
to patients with a very high chance of becoming sterile due to
their treatment. One whole ovary should then be cryopre-
served, whereas a large biopsy can be obtained from the ovary
that is left in situ to obtain tissue strips. These cortex strips may
be used as a backup strategy, should the autotransplantation of
the whole ovary fail.
In this study, we identified a number of crucial parameters
for optimizing the quality of cryopreserved and subsequently
thawed (human) intact ovaries. These include the time be-
tween surgical removal of the ovary and start of the cryopres-
ervation process (as short as possible), the optimal cryopro-
tectant (DMSO), the preferred technique to administer the
cryoprotectant to the intact ovary (combining perfusion with
submersion), and finally, the optimal perfusion/submersion
time in DMSO (60 min).
In conclusion, whole ovarian autotransplantation in
humans still has a number of obstacles to overcome.
Nevertheless, our optimized cryopreservation procedure rep-
resents an important step in introducing whole ovary
autotransplantation in clinically applied fertility preservation.
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control ovary
Cryopreserved/thawed
ovary
small vessels large vesselsFig. 7 Fresh and cryopreserved
human ovarian tissue stained
immunohistochemically with
anti-human factor VIII antibody
to highlight endothelial cells. No
apparent damage to the vascular
endothelial cell layer is visible in
the cryopreserved/thawed
ovaries. Note the presence of
erythrocytes in the vessels of the
fresh tissue, which are lacking in
the perfused cryopreserved
ovarian tissue
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